Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
Completed
Ohio State University
Phase 3
1992-06-01
OBJECTIVES:
I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in
patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic
paralysis, and hypokalemic periodic paralysis.
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
Completed
National Center for Research Resources (NCRR)
Phase 3
1992-06-01
OBJECTIVES:
I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in
patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic
paralysis, and hypokalemic periodic paralysis.
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 3
2007-06-01
The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance)
for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and
hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of
Dichlorphenamide in periodic paralysis.
The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance)
for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and
hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of
Dichlorphenamide in periodic paralysis.
This preview shows a limited data set Subscribe for full access, or try a Trial
Dichlorphenamide clinical trials update, market analysis and forecast: pipeline status, competitive landscape, and revenue projection
Last updated: August 1, 2026
No current, verifiable market authorization status, FDA/EMA regulatory status, or active clinical-trial identifiers for dichlorphenamide were provided in the request. Without authoritative, source-backed inputs (trial registries, labeled indications, approvals, and sales/reimbursement data), a complete and accurate clinical-trials update and market projection cannot be produced.
What is dichlorphenamide’s current clinical development status and which trials are active?
Answer: Not provided.
Which indications have ongoing dichlorphenamide Phase 1–3 trials?
Answer: Not provided.
What are the trial identifiers (NCT/EudraCT) and recruitment statuses?
Answer: Not provided.
What is the regulatory status of dichlorphenamide in the US and Europe?
Answer: Not provided.
What is the FDA approval status of dichlorphenamide and its labeled indication(s)?
Answer: Not provided.
What is the EMA status and any orphan-designation or similar incentives?
Answer: Not provided.
What is the competitive landscape for dichlorphenamide by mechanism and target patient population?
Answer: Not provided.
Which branded and generic alternatives compete with dichlorphenamide?
Answer: Not provided.
How does dichlorphenamide compare with acetazolamide and other carbonic anhydrase inhibitors?
Answer: Not provided.
How does dichlorphenamide’s market size evolve and what drives demand?
Answer: Not provided.
What are the key demand drivers (incidence, treatment guidelines, payer coverage)?
Answer: Not provided.
What are the key constraints (safety profile, adherence, administration, monitoring)?
Answer: Not provided.
What revenue forecast is possible for dichlorphenamide through 2035?
Answer: Not provided.
What baseline sales assumptions are required for the forecast?
Answer: Not provided.
What scenarios change the projection (new indication, label expansion, generic entry)?
Answer: Not provided.
When does dichlorphenamide face generic entry or exclusivity loss?
Answer: Not provided.
What Orange Book patents and exclusivities apply to dichlorphenamide?
Answer: Not provided.
Are there Paragraph IV challenges or settlements affecting launch timelines?
Answer: Not provided.
Key Takeaways
Answer: Not provided.
FAQs
What are the latest dichlorphenamide trial results by endpoint and timeline? Not provided.
Is dichlorphenamide approved for any specific rare condition or orphan indication? Not provided.
Which companies are developing competing carbonic anhydrase inhibitor therapies? Not provided.
What is the risk of generic or biosimilar-like competition for dichlorphenamide? Not provided.
How do safety monitoring requirements affect real-world use and revenue? Not provided.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
